#JPM23: Did the IRA kill that drug?
Pharma companies were loud and clear ahead of the passage of Medicare price setting legislation in the Inflation Reduction Act: Once passed, drugs that no longer worked in the new math of the legislation would need to be cut.
And within weeks of the law being enacted, we began to see that happen, with companies like Eli Lilly and Alnylam claiming early stage assets had to be shut down. Moving forward, what’s to stop any company from claiming that every pipeline deletion is the result of the IRA? How big will the impact really be? What else should be expected? And are developers simply finding a convenient villain to blame? Tune in below to find out more from the experts.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.